Focus Stocks
Close to Key Levels: GlaxoSmithKline
Published on Wednesday, 16 May 2012 07:52 Written by TradersHuddle Wire
New York, May 16th (TradersHuddle.com) - GlaxoSmithKline plc (NYSE:GSK) closed the trading day at $45.47, near its 50 day and 200 day moving averages set at $45.64 and $44.11 respectively. GlaxoSmithKline's price action placed the stock above the 200 day moving average but below its 50 day moving average, a setup that signals a possible break out.
GlaxoSmithKline plc (NYSE:GSK) is a research-based pharmaceutical group that develops, manufactures and markets vaccines, prescription and over-the-counter medicines, as well as health-related consumer products. Its over the counter medicines and health related consumer products are marketed under brand names like Panadol, Nicorette, Breathe Right, Tums, Aquafresh, and Sensodyne among others.
GlaxoSmithKline seems to be setting up for a tight range between the 200 day moving average as support and the 50 day moving average serving as resistance.
A tiered approach, appears to be the best strategy to maximize possible movements in the stock, as traders could establish a small position in GlaxoSmithKline and wait for the stock to break out above its 50 day moving average at $45.64. Then they could add to the position as momentum builds with the breakout. On the flip side, if support being referenced at the 200 day moving average set at $44.11 breaks, it could signal further downside pressure for GlaxoSmithKline.
Related Articles
- GlaxoSmithKline Is Near a Key Resistance Area
- BREO™ ELLIPTA™ gains US approval for the treatment of COPD
- Trading Idea: - Is GlaxoSmithKline close to Resistance?
- GlaxoSmithKline Is Moving Above Resistance
- GlaxoSmithKline Is Near a Key Resistance Area
- GlaxoSmithKline Is Moving Above Resistance
- GlaxoSmithKline CFO Interviewed on Q1 2013 Financial Results
- GlaxoSmithKline Is Near a Key Resistance Area
- Above Resistance: GlaxoSmithKline
- FDA Advisory Committee recommends approval of BREO™ ELLIPTA™ for the treatment of COPD
Related Partner Headlines
- GlaxoSmithKline Stock To Go Ex-dividend Tomorrow (GSK) - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Drugs Laggard - TheStreet.com
- Buzz on Sarepta's Eteplirsen From London Duchenne Meeting - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Health Care Winner - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Health Care Winner - TheStreet.com
- United Therapeutics Could Lose The Battle For PAH Therapies - TheStreet.com
- A Prescription for Election Fever - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Drugs Laggard - TheStreet.com
- How to Hedge Profits in Sarepta Therapeutics - TheStreet.com
- Lazard Analyst Note on Sarepta Therapeutics Is Generating Buzz - TheStreet.com
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,297.04 Trade time:1:01PM EDT Value change:▼10.13 (-0.07%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,649.77 Trade time:1:01PM EDT Value change:▼5.58 (-0.34%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,457.77 Trade time:1:01PM EDT Value change:▼5.53 (-0.16%)In The Wires
-
Toronto Stock Exchange and TSX Venture Exchange Travel to Latin America -
Momentum Named Best in Sports Event and Experiential Marketing at 2013 Sports Business Awards -
Epazz, Inc. will file 10k next week and 10q will follow shortly after -
Palms Casino Resort Debuts Completely Redesigned Palms.com Website, May 23 -
ClickSoftware Announces 2013 Annual General Meeting of Shareholders to be Held on July 8, 2013 -
AT&T 4G LTE Takes Top Spot In Boston In 2013 PCWorld/TechHive Speed Tests -
TELUS welcomes Mobilicity debtholder vote in favour of acquisition -
2013 Hurricane Season Activity Predicted To Be Above Average








